However, the ROC analysis did not show p < 0.05 in the prediction of either the recurrence or survival status in the mutation of PIK3CA in tumor tissue DNA alone or of the other two SNVs (KRT6A F249L and KRAS G12V) in either tumor tissue DNA, or circulating DNA collected before treatment or during follow-up. This evidence concerns the gene KRAS and neoplasm.